- Home
- UTHR vs XPEV Comparison
UTHR vs XPEV Comparison
Compare UTHR & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- XPEV
- Stock Information
- Founded
- UTHR 1996
- XPEV 2015
- Country
- UTHR United States
- XPEV China
- Employees
- UTHR N/A
- XPEV N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- XPEV Auto Manufacturing
- Sector
- UTHR Health Care
- XPEV Consumer Discretionary
- Exchange
- UTHR Nasdaq
- XPEV Nasdaq
- Market Cap
- UTHR 14.4B
- XPEV 12.0B
- IPO Year
- UTHR 1999
- XPEV 2020
- Fundamental
- Price
- UTHR $308.00
- XPEV $19.59
- Analyst Decision
- UTHR Buy
- XPEV Buy
- Analyst Count
- UTHR 12
- XPEV 8
- Target Price
- UTHR $392.00
- XPEV $21.71
- AVG Volume (30 Days)
- UTHR 439.7K
- XPEV 8.4M
- Earning Date
- UTHR 04-30-2025
- XPEV 05-20-2025
- Dividend Yield
- UTHR N/A
- XPEV N/A
- EPS Growth
- UTHR 18.86
- XPEV N/A
- EPS
- UTHR 25.10
- XPEV N/A
- Revenue
- UTHR $2,994,100,000.00
- XPEV $5,598,814,778.00
- Revenue This Year
- UTHR $11.45
- XPEV $99.59
- Revenue Next Year
- UTHR $6.11
- XPEV $35.36
- P/E Ratio
- UTHR $12.27
- XPEV N/A
- Revenue Growth
- UTHR 19.84
- XPEV 33.22
- 52 Week Low
- UTHR $260.41
- XPEV $6.60
- 52 Week High
- UTHR $417.82
- XPEV $27.16
- Technical
- Relative Strength Index (RSI)
- UTHR 57.25
- XPEV 49.88
- Support Level
- UTHR $290.02
- XPEV $19.08
- Resistance Level
- UTHR $319.40
- XPEV $20.04
- Average True Range (ATR)
- UTHR 10.02
- XPEV 0.57
- MACD
- UTHR 2.72
- XPEV 0.07
- Stochastic Oscillator
- UTHR 69.99
- XPEV 57.06
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.